PSC, AIH and overlap syndrome in inflammatory bowel disease

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 5, 2012, Pages 420-436

  Trivedi, P J ^a   Chapman, R W ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BILE ACID; URSODEOXYCHOLIC ACID;

AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CHOLESTASIS; CLINICAL FEATURE; COLON DISEASE; COLORECTAL CANCER; END STAGE LIVER DISEASE; ENTERITIS; FATIGUE; GENETICS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPHOCYTE HOMING; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; SHORT SURVEY; ULCERATIVE COLITIS;

CHOLANGITIS, SCLEROSING; HEPATITIS, AUTOIMMUNE; HUMANS; INFLAMMATORY BOWEL DISEASES; SYNDROME;

EID: 84868344438     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.10.007     Document Type: Short Survey

References (191)

1. Thomas C.H. Ulceration of the colon with a much enlarged fatty liver. Trans Pathol Soc Phil 1873, 4:87-88.
2. Lister J.D. A specimen of diffuse ulcerative colitis with secondary diffuse hepatitis. Trans Pathol Soc Lon 1899, 50:130-134.
3. Angulo P., Lindor K.D. Primary sclerosing cholangitis. Hepatology 1999, 30:325-332.
4. Bambha K., Kim W.R., Talwalkar J., Torgerson H., Benson J.T., Therneau T.M., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364-1369.
5. Kingham J.G., Kochar N., Gravenor M.B. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004, 126:1929-1930.
6. Escorsell A., Pares A., Rodes J., Solis-Herruzo J.A., Miras M., de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994, 21:787-791.
7. Ponsioen C.Y., Vrouenraets S.M., Prawirodirdjo W., Rajaram R., Rauws E.A., Mulder C.J., et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002, 51(4):562-566.
8. Broomé U., Olsson R., Lööf L., Bodemar G., Hultcrantz R., Danielsson A., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38(4):610-615.
9. Tischendorf J.J., Hecker H., Krüger M., Manns M.P., Meier P.N. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007, 102(1):107-114.
10. Perrett A.D., Higgins G., Johnston H.H., Massarella G.R., Truelove S.C., Wright R. The liver in ulcerative colitis. Q J Med 1971, 40:211-238.
11. Olsson R., Danielsson A., Jarnerot G., Lindström E., Lööf L., Rolny P., et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991, 100:1319-1323.
12. Schrumpf E., Elgjo K., Fausa O., Gjone E., Kolmannskog F., Ritland S. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980, 15:689-697.
13. Okada H., Mizuno M., Yamamoto K., Tsuji T. Primary sclerosing cholangitis in Japanese patients: association with inflammatory bowel disease. Acta Med Okayama 1996, 50(5):227-235.
14. Takikawa H., Takamori Y., Tanaka A., Kurihara H., Nakanuma Y. Analysis of 388 cases of primary sclerosing cholangitis in Japan; presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 2004, 29(3):153-159.
15. Halliday J.S., Djordjevic J., Culver E., Travis S., Lust M., Braden B., et al. PSC-Crohns disease: characterisation of this patient group for the first time reveals a unique clinical phenotype. J Hepatol 2011, 4(Suppl.):s510.
16. Bergquist A., Lindberg G., Saarinen S., Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005, 42:252-256.
17. Bergquist A., Montgomery S.M., Bahmanyar S., Olsson R., Danielsson A., Lindgren S., et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008, 6:939-943.
18. Karlsen T.H., Franke A., Melum E., Kaser A., Hov J.R., Balschun T., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010, 138:1102-1111.
19. Melum E., Franke A., Schramm C., Weismüller T.J., Gotthardt D.N., Offner F.A., et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011, 43(1):17-19.
20. Janse M., Lamberts L.E., Franke L., Raychaudhuri S., Ellinghaus E., Muri Boberg K., et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 2011, 53(6):1977-1985.
21. Saarinen S., Olerup O., Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:3195-3199.
22. Levy C., Lindor K.D. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006, 26(1):22-30.
23. Pokorny C.S., Norton I.D., McCaughan G.W., Selby W.S. Anti-neutrophil cytoplasmic antibody: a prognostic indicator in primary sclerosing cholangitis. J Gastroenterol Hepatol 1994, 9:40-44.
24. Bansi D.S., Bauducci M., Bergqvist A., Boberg K., Broome U., Chapman R., et al. Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. Eur J Gastroenterol Hepatol 1997, 9:575-580.
25. Terjung B., Spengler U., Sauerbruch T., Worman H.J. Atypical p-ANCA in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000, 119:310-322.
26. Terjung B., Söhne J., Lechtenberg B., Gottwein J., Muennich M., Herzog V., et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010, 59(6):808-816.
27. Xu B., Broome U., Ericzon B.G., Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 2002, 51:120-127.
28. Karrar A., Broome U., Sodergren T., Jaksch M., Bergquist A., Björnstedt M., et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007, 132:1504-1514.
29. Angulo P., Peter J.B., Gershwin M.E., DeSotel C.K., Shoenfeld Y., Ahmed A.E., et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000, 32:182-187.
30. O'Mahony C.A., Vierling J.M. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006, 26:3-21.
31. Bo X., Broome U., Remberger M., Sumitran-Holgersson S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 2001, 49:131-141.
32. Eksteen B., Curbishley S.M., Lai W.K., Adams D.H. Liver dendritic cells in primary sclerosing cholangitis (PSC) are unable to imprint mucosal adhesion molecules in primed lymphocytes without exogenous retinoic acid. J Hepatol 2006, 44:S10.
33. Eksteen B., Grant A.J., Miles A., Curbishley S.M., Lalor P.F., Hübscher S.G., et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004, 200:1511-1517.
34. Grant A.J., Lalor P.F., Hubscher S.G., Briskin M., Adams D.H. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001, 33:1065-1075.
35. Eksteen B., Miles A.E., Grant A.J., Adams D.H. Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease. Clin Med 2004, 4:173-180.
36. Grant A.J., Lalor P.F., Salmi M., Jalkanen S., Adams D.H. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002, 359:150-157.
37. Adams D., Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006, 6:244-251.
38. Liaskou E., Karikoski M., Reynolds G.M., Lalor P.F., Weston C.J., Pullen N., et al. Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology 2011, 53(2):661-672.
39. van Erpecum K.J., Smits S.J., van de Meeberg P.C., Linn F.H., Wolfhagen F.H., van Berge-Henegouwen G.P., et al. Risk of primary sclerosing cholangitis is associated with non-smoking behavior. Gastroenterology 1996, 110:1503-1506.
40. Loftus E.V., Sandborn W.J., Tremaine W.J., Mahoney D.W., Zinsmeister A.R., Offord K.P., et al. Primary sclerosing cholangitis is associated with nonsmoking: a case control study. Gastroenterology 1996, 110:1496-1502.
41. Cohen R.D., Hanauer S.B. Protection from primary sclerosing cholangitis: smoke trails of just coattails?. Gastroenterology 1996, 110:1658-1662.
42. Fickert P., Fuchsbichler A., Wagner M., Zollner G., Kaser A., Tilg H., et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004, 127:261-274.
43. Pauli-Magnus C., Kerb R., Fattinger K., Lang T., Anwald B., Kullak-Ublick G.A., et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2004, 39:779-791.
44. Girodon E., Sternberg D., Chazouilleres O., Cazeneuve C., Huot D., Calmus Y., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene defects in patients with primary sclerosing cholangitis. J Hepatol 2002, 37:192-197.
45. Gallegos-Orozco J.F., Yurk E., Wang C., Wang N., Rakela N., Charlton J., et al. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol 2005, 100:874-878.
46. Sheth S., Shea J.C., Bishop M.D., Chopra S., Regan M.M., Malmberg E., et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003, 113:286-292.
47. Bungay H., Buchel O.C., Cummings F., Travis S.P.L., Chapman R.W. Prevalence and determinants of primary sclerosing cholangitis in a cohort of patients with inflammatory bowel disease and normal liver function tests. Gut 2008, 57(Suppl. 1):A41.
48. Loftus E.V., Harewood G.C., Loftus C.G., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
49. Lindberg B.U., Broome U., Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001, 44:77-85.
50. Guicciardi M.E., Gores G.J. Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways. Hepatology 2002, 35:971-973.
51. Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36:525-531.
52. Harnois D.M., Angulo P., Jorgensen R.A., Larusso N.F., Lindor K.D. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558-1562.
53. Okolicsanyi L., Groppo M., Floreani A., Morselli-Labate A.M., Rusticali A.G., Battocchia A., et al. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig Liver Dis 2003, 35:325-331.
54. O'Brien C.B., Senior J.R., Arora-Mirchandani R., Batta A.K., Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991, 14:838-847.
55. De Maria N., Colantoni A., Rosenbloom E., Van Thiel D.H. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 1996, 43:1472-1479.
56. Lindor K.D. Ursodiol for primary sclerosing cholangitis: Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-695.
57. van Hoogstraten H.J., Wolfhagen F.H., van de Meeberg P.C., Kuiper H., Nix G.A., Becx M.C., et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single vs. multiple daily doses. J Hepatol 1998, 29:417-423.
58. Shi J., Li Z., Zeng X., Lin Y., Xie W.F. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res 2009, 39:865-873.
59. Chen W., Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2003, 2:CD003626.
60. Poropat G., Giljaca V., Stimac D., Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2011, 1:CD003626.
61. Mitchell S.A., Bansi D.S., Hunt N., Von Bergmann K., Fleming K.A., Chapman R.W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900-907.
62. Beuers U., Spengler U., Kruis W., Aydemir U., Wiebecke B., Heldwein W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial. Hepatology 1992, 16:707-714.
63. Stiehl A., Walker S., Stiehl L., Rudolph G., Hofmann W.J., Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994, 20:57-64.
64. Cullen C., Rust C., Fleming K., Edward C., Beuers U., Chapman R.W. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008, 48:792-800.
65. Olsson R., Boberg K.M., de Muckadell O.S., Lindgren S., Hultcrantz R., Folvik G., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464-1472.
66. Lindor K.D., Kowdley K.V., Luketic V.A., Harrison M.E., McCashland T., Befeler A.S., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50(3):808-814.
67. Benedetti A., Alvaro D., Bassotti C., Gigliozzi A., Ferretti G., La Rosa T., et al. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology 1997, 26:9-21.
68. Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Weiglein A.H., Lammert F., et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002, 123:1238-1251.
69. Triantos C.K., Koukias N.M., Nikolopoulou V.N., Meta-analysis: BurroughsA.K. ursodeoxycholic acid forprimary sclerosing cholangitis. Aliment Pharmacol Ther 2011, 34(8):901-910.
70. Bjornsson E., Lindqvist-Ottosson J., Asztely M., Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:502-508.
71. Hammel P., Couvelard A., O'Toole D., Ratouis A., Sauvanet A., Fléjou J.F., et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001, 344:418-423.
72. Stiehl A., Rudolph G., Sauer P., Benz C., Stremmel W., Walker S., et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997, 26:560-566.
73. Stiehl A., Rudolph G., Kloters-Plachky P., Sauer P., Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002, 36:151-156.
74. Cullen S., Chapman R.W. Review of the current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 21:933-948.
75. Solano E., Khakhar A., Bloch M., Quan D., McAlister V., Ghent C., et al. Liver transplantation for primary sclerosing cholangitis. Transplant Proc 2003, 35:2431-2434.
76. Maheshwari A., Yoo H.Y., Thuluvath P.J. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004, 99:538-542.
77. Farges O., Malassagne B., Sebagh M., Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995, 117:146-155.
78. Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011 Sep 2 [Epub ahead of print].
79. Boberg K.M., Bergquist A., Mitchell S., Pares A., Rosina F., Broomé U., et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002, 37(10):1205-1211.
80. Rudolph G., Gotthardt D., Kloeters-Plachky P., Rost D., Kulaksiz H., Stiehl A., et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 2010, 53(2):313-317.
81. Broome U., Lofberg R., Veress B., Eriksson L.S. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995, 22:1404-1408.
82. Soetikno R.M., Lin O.S., Heidenreich P.A., Young H.S., Blackstone M.O. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a metaanalysis. Gastrointest Endosc 2002, 56(1):48-54.
83. Jess T., Loftus E.V., Velayos F.S., Winther K.V., Tremaine W.J., Zinsmeister A.R., et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007, 102(4):829-836.
84. Marelli L., Xirouchakis E., Kalambokis G., Cholongitas E., Hamilton M.I., Burroughs A.K. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?. Gut 2011, 60(9):1224-1228.
85. Hill M.J., Melville D.M., Lennard-Jones J.E., Neale K., Ritchie J.K. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987, 2:185-186.
86. Bayerdorffer E., Mannes G.A., Richter W.O., Ochsenkühn T., Wiebecke B., Köpcke W., et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993, 104:145-151.
87. Stadler J., Yeung K.S., Furrer R., Marcon N., Himal H.S., Bruce W.R. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. Cancer Lett 1988, 38:315-320.
88. Rodrigues C.M., Fan G., Wong P.Y., Kren B.T., Steer C.J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998, 4:165-178.
89. Ochsenkuhn T., Bayerdorffer E., Meining A., Schinkel M., Thiede C., Nüssler V., et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999, 85:1664-1669.
90. Heuschen U.A., Hinz U., Allemeyer E.H., Stern J., Lucas M., Autschbach F., et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001, 120:841-847.
91. Martinez J.D., Stratagoules E.D., LaRue J.M., Powell A.A., Gause P.R., Craven M.T., et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998, 31:111-118.
92. Tung B.Y., Emond M.J., Haggitt R.C., Bronner M.P., Kimmey M.B., Kowdley K.V., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89-95.
93. Pardi D.S., Loftus E.V., Kremers W.K., Keach J., Lindor K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.
94. Wolf J.M., Rybicki L.A., Lashner B.A. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 22(9):783-788.
95. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106(9):1638-45.
96. Beuers U., Boberg K.M., Chapman R.W., Chazouillères O., Invernizzi P., Jones D.E.J., et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267.
97. Cairns S.R., Scholefield J.H., Steele R.J., Dunlop M.G., Thomas H.J., Evans G.D., et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010, 59:666-690.
98. Villamil A., De Paula J.A., Galdame O., Piccioni H., Ciardullo M., De Santibañes E., et al. Clinical course of inflammatory bowel disease in patients transplanted for primary sclerosing cholangitis. Acta Gastroenterol Latinoam 2008, 38(4):252-259.
99. Moncrief K.J., Savu A., Ma M.M., Bain V.G., Wong W.W., Tandon P. The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation-a single-centre experience. Can J Gastroenterol 2010, 24(1):40-46.
100. Hanouneh IA, Macaron C, Lopez R, Zein NN, Lashner BA. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis 2011 [Epub ahead of print]. doi:10.1002/ibd.21692.
101. Rubin P.H., Friedman S., Harpaz N., Goldstein E., Weiser J., Schiller J., et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999, 117:1295-1300.
102. Engelsgjerd M., Farraye F.A., Odze R.D. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999, 117:1288-1294.
103. Blackstone M.O., Riddell R.H., Rogers B.H., Levin B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology 1981, 80:366-374.
104. Bernstein C.N., Shanahan F., Weinstein W.M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 1994, 343:71-74.
105. Stahlberg D., Veress B., Tribukait B., Broome U. Atrophy and neoplastic transformation of the ileal pouch in patients with UC and PSC: a case control study. Dis Colon Rectum 2003, 46(6):770-778.
106. Oresland T. Review article: colon-saving medical therapy vs. colectomy in ulcerative colitis-the case for colectomy. Aliment Pharmacol Ther 2006, 24(Suppl. 3):74-79.
107. Walker M., Radley S. Adenocarcinoma in an ileoanal pouch formed for ulcerative colitis in a patient with primary sclerosing cholangitis and a liver transplant: report of a case and review of the literature. Dis Colon Rectum 2006, 49(6):909-912.
108. Benavente-Chenhalls L., Mathis K.L., Dozois E.J., Cima R.R., Pemberton J.H., Larson D.W. Laparoscopic ileal pouch-anal anastomosis in patients with chronic ulcerative colitis and primary sclerosing cholangitis: a case-matched study. Dis Colon Rectum 2008, 51:549-555.
109. Card T., Solaymani-Dodaran M., West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol 2008, 48:939-944.
110. Berndtsson I., Lindholm E., Oresland T., Borjesson L. Longterm outcome after ileal pouch-anal anastomosis: function and health-related quality of life. Dis Colon Rectum 2007, 50:1545-1552.
111. Borjesson L., Willen R., Haboubi N., Duff S.E., Hulten L. The risk of dysplasia and cancer in the ileal pouch mucosa after restorative proctocolectomy for ulcerative proctocolitis is low: a long-term follow-up study. Colorectal Dis 2004, 6:494-498.
112. Laureti S., Ugolini F., D'Errico A., Rago S., Poggioli G. Adenocarcinoma below ileoanal anastomosis for ulcerative colitis: report of a case and review of the literature. Dis Colon Rectum 2002, 45(3):418-421.
113. Ferrante M., Declerck S., Hertogh G., Van Assche G., Geboes K., Rutgeerts P., et al. Outcome after proctocolectomy with an ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis 2008, 14(1):20-28.
114. Kartheuser A.H., Dozois R.R., Wiesner R.H., LaRusso N.F., Ilstrup D.M., Schleck C.D. Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis. Ann Surg 1993, 217(4):314-320.
115. Penna C., Dozois R., Tremaine W., Sandborn W., LaRusso N., Schleck C., et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996, 38:234-239.
116. Aitola P., Matikainen M., Mattila J., Tomminen T., Hiltunen K.M. Chronic inflammatory changes in the pouch mucosa are associated with cholangitis found on peroperative liver biopsy specimens at restorative proctocolectomy for ulcerative colitis. Scand J Gastroenterol 1998, 33:289-293.
117. Gorgun E., Remzi F.H., Manilich E., Preen M., Shen B., Fazio V.W. Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case control study. Surgery 2005, 138:631-639.
118. Lepisto A., Karkkainen P., Jarvinen H.J. Prevalence of primary sclerosing cholangitis in ulceratice colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis. Inflamm Bowel Dis 2008, 14(6):775-779.
119. Zins B.J., Sandborn W.J., Penna C.R., Landers C.J., Targan S.R., Tremaine W.J., et al. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol 1995, 90(12):2177-2181.
120. Freeman K., Shao Z., Remzi F.H., Lopez R., Fazio V.W., Shen B. Impact of orthotopic liver transplant for PSC on chronic antibiotic refractory pouchitis. Clin Gastroenterol Hepatol 2008, 6(1):62-68.
121. Mathis K.L., Dozois E.J., Larson D.W., Cima R.R., Sarmiento J.M., Wolff B.G., et al. Ileal pouch-anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis. Br J Surg 2008, 95(7):882-886.
122. Kartheuser A.H., Dozois R.R., LaRusso N.F., Wiesner R.H., Ilstrup D.M., Schleck C.D. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. Mayo Clin Proc 1996, 71(8):748-756.
123. Björnsson E., Boberg K.M., Cullen S., Fleming K., Clausen O.P., Fausa O., et al. Patients with small duct primary sclerosing cholangitis have a favorable long-term prognosis. Gut 2002, 51:731-735.
124. Broomé U., Glaumann H., Lindstöm E., Lööf L., Almer S., Prytz H., et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002, 36:586-589.
125. Angulo P., Maor-Kendler Y., Lindor K.D. Small-duct primary sclerosing cholangitis: prevalence and natural history. Hepatology 2002, 35:1494-1500.
126. Bjornsson E., Olsson R., Berquist A., Lindgren S., Braden B., Chapman R.W., et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008, 134:975-980.
127. Ngu J.H., Bechly K., Chapman B.A., et al. Population-based epidemiology study autoimmune hepatitis-a disease of older women?. J Gastroenterol Hepatol 2010, 25:1681-1686.
128. Czaja A.J., Manns M.P. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010, 139:58-72.
129. Teufel A., Weinmann A., Kahaly G.J., Centner C., Piendl A., Wörns M., et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010, 44(3):208-213.
130. Gregorio G.V., Portmann B., Karani J., Harrison P., Donaldson P.T., Vergani D., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33:544-553.
131. Oliveira L.C., Porta G., Marin M.L., Bittencourt P.L., Kalil J., Goldberg A.C. Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev 2011, 10(4):189-193.
132. Ahmad T., Marshall S.E., Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. World J Gastroenterol 2006, 12(23):3628-3635.
133. Wen L., Peakman M. T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet 1990, 336:1527-1530.
134. Wen L., Ma Y. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med 2001, 1:379-389.
135. Longhi M.S., Hussain M.J. Cytochrome P450IID6-specificCD8T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007, 46:472-484.
136. Ma Y., Bogdanos D.P. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006, 130:868-882.
137. Johnson P.J., Mcfarlane I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993, 18(4):998-1005.
138. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31(5):929-938.
139. Hennes E.M., Zeniya M., Czaja A.J., Pares A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48(1):169-176.
140. Czaja A.J. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008, 48(5):1540-1548.
141. Poupon R. Autoimmune overlapping syndromes. Clin Liver Dis 2003, 7:865-878.
142. Carpenter H.A., Czaja A.J. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002, 6:685-705.
143. Strassburg C.P., Manns M.P. Treatment of autoimmune hepatitis. Semin Liver Dis 2009, 29(3):273-285.
144. Feld J.J. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005, 42(1):53-62.
145. Trivedi P.J., Cullen S. Autoimmune hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Dig Dis Sci 2011, 56(2):276-278.
146. Wong R.J., Gish R., Frederick T., Bzowej N., Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci 2011, 56(2):578-585.
147. Seibold F., Weber P., Jenss H., Scheurlen M. Autoimmune hepatitis in inflammatory bowel disease: report of two unusual cases. Z Gastroenterol 1997, 35:29-32.
148. Linares P., Vivas S., Olcoz J.L. Autoimmune hepatitis associated with the antiphospholipid syndrome and ulcerative colitis. Eur J Intern Med 2005, 16:376.
149. Cronin E.M., Sibartie V., Crosbie O.M., Quigley E.M. Autoimmune hepatitis in association with lymphocytic colitis. J Clin Gastroenterol 2006, 40:648-650.
150. Perdigoto R., Carpenter H.A., Czaja A.J. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992, 14(2-3):325-331.
151. Al-Chalabi T., Portmann B.C., Bernal W., et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008, 28:209-220.
152. van Buuren H.R., van Hoogstraten H.J.E., Terkivatan T., Schalm S.W., Vleggaar F.P. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000, 33:543-548.
153. Abdo A.A., Bain V.G., Kichian K., Lee S.S. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002, 36(6):1393-1399.
154. Floreani A., Rizzotto E.R., Ferrara F., Carderi I., Caroli D., Blasone L., et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005, 100:1516-1522.
155. Lewin M., Vilgrain V., Ozeme V., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009, 50:528-537.
156. El-Shabrawi M., Wilkinson M.L., Portmann B., Mieli-Vergani G., Chong S.K., Williams R., et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987, 92:1226-1235.
157. Boberg K.M., Fausa O., Haaland T., Holter E., Mellbye O.J., Spurkland A., et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996, 23:1369-1376.
158. Abdalian R., Dhar P., Jhaverik K., Haider M., Guindi M., Heathcote E.J., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008, 47:949-957.
159. Gohlke F., Lohse A.W., Dienes H.P., Lohr H., Marker-Hermann E., Gerken G., et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996, 24:699-705.
160. McNair A.N.B., Moloney M., Portmann B.C., Williams R., McFarlane I.G. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998, 93:777-784.
161. Boberg K.M., Chapman R.W., Hirschfield G.M., Lohse A.W., Manns M.P., Schrumpf E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011, 54(2):374-385.
162. Boberg K.M., Egeland T., Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003, 38:991-995.
163. Olsson R., Glaumann H., Almer S., Broomé U., Lebrun B., Bergquist A., et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009, 20:190-196.
164. Chapman R., Fevery J., Kalloo A., Nagorney D.M., Boberg K.M., Shneider B., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51:660-678.
165. Lüth S., Kanzler S., Frenzel C., Kasper H.U., Dienes H.P., Schramm C., et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol 2009, 43:75-80.
166. Silveira M.G., Lindor K.D. Overlap syndromes with autoimmune hepatitis in chronic cholestatic liver diseases. Expert Rev Gastroenterol Hepatol 2007, 1:329-340.
167. Czaja A.J., Carpenter H.A., Santrach P.J., Moore S.B. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000, 31:1231-1238.
168. Kaya M., Angulo P., Lindor K.D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000, 33:537-542.
169. Arai O., Ikeda H., Mouri H., Notohara K., Matsueda K. Two cases of inflammatory bowel disease diagnosed in the course of primary biliary cirrhosis. Nihon Shokakibyo Gakkai Zasshi 2010, 107(6):900-908.
170. Tsuda M, Ambrosini YM, Zhang W, Yang GX, Ando Y, Rong G, et al. Fine phenotypic and functional characterization of effector CD8(+) T cells in patients with primary biliary cirrhosis. Hepatology 2011 Jul 6; [Epub ahead of print]. doi:10.1002/hep.24526.
171. Molodecky N.A., Kareemi H., Parab R., Barkema H.W., Quan H., Myers R.P., et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011, 53(5):1590-1599.
172. Lindkvist B., Benito de Valle M., Gullberg B., Björnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010, 52(2):571-577.
173. Boberg K.M., Aadland E., Jahnsen J., Raknerud N., Stiris M., Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103.
174. Wiencke K., Spurkland A., Schrumpf E., Boberg K.M. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology 2001, 34:625-630.
175. Mieli-Vergani G., Vergani D. Autoimmune paediatric liver disease. World J Gastroenterol 2008, 14(21):3360-3367.
176. Mieli-Vergani G., Vergani D. Unique features of primary sclerosing cholangitis in children. Curr Opin Gastroenterol 2010, 26(3):265-268.
177. Jørgensen KK, Grzyb K, Lundin KE, Clausen OP, Aamodt G, Schrumpf E, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2011 Mar 31; [Epub ahead of print]. doi:10.1002/ibd.21699.
178. Dinesen L.C., Walsh A.J., Protic M.N., Heap G., Cummings F., Warren B.F., et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010, 4(4):431-437.
179. White E., Melmed G.Y., Vasiliauskas E.A., Dubinsky M., Berel D., Targan S.R., et al. A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitis. Dis Colon Rectum 2010, 53(7):987-994.
180. Haskell H., Andrews C.W., Reddy S.I., Dendrinos K., Farraye F.A., Stucchi A.F., et al. Pathologic features and clinical significance of " backwash" ileitis in ulcerative colitis. Am J Surg Pathol 2005, 29(11):1472-1481.
181. Lazaridis K.N., Gores G.J. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006, 26:42-51.
182. Fevery J., Verslype C., Lai G., Aerts R., Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007, 52(11):3123-3135.
183. Brandsaeter B., Isoniemi H., Broome U., Olausson M., Bäckman L., Hansen B., et al. Liver transplantation for primary sclerosing cholangitis: predictors and consequences of hepatobiliary malignancy. J Hepatol 2004, 40:815-822.
184. Rudolph G., Kloeters-Plachky P., Rost D., Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2007, 19:487-491.
185. Lewis J.T., Talwalkar J.A., Rosen C.B., Smyrk T.C., Abraham S.C. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia dysplasia-carcinoma sequence. Am J Surg Pathol 2007, 31:907-913.
186. Buckles D.C., Lindor K.D., Larusso N.F., Petrovic L.M., Gores G.J. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002, 97:1138-1142.
187. Bruix J., Sherman M. AASLD practice guideline. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022.
188. Kitiyakara T., Chapman R.W. Chemoprevention and screening in primary sclerosing cholangitis. Postgrad Med J 2008, 84(991):228-237.
189. Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Lööf L., Danielsson A., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327.
190. Czaja A.J. Autoimmune hepatitis. In: Sleisenger and Fordtran's gastrointestinal and liver disease 1998, WB Saunders Company, Philadelphia, Pa, p. 1265-74. 6th ed.
191. Ma Y., Okamoto M. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002, 35:658-664.